in blood drawn 10 minutes after rapid i.v. injection of heparin. The heparin (Liquaemin sodium, Organon) was administered in a dose of 60 U/kg body weight immediately after the fasting blood specimens were drawn. The blood for lipase activity was drawn into chilled tubes, centrifuged at 4°C, and quickly frozen to -20°C for later assay. Tapering of nondiuretic antihypertensive drugs, if prescribed, was then begun.
One week after cessation of nondiuretic drugs, the diuretic agents were stopped. The drugs prescribed and the duration of treatment at the time of the initial blood sampling are listed in table 1. After discontinuance of drugs, patients were seen at intervals of 1-4 weeks. When diastolic blood pressure was greater than 90 mm Hg on two consecutive visits, the patients were asked to report fasting at the next visit for repeat blood studies. In eight patients, diastolic pressure had not increased above 90 mm Hg at the time of repeat blood sampling. Three of these eight patients were studied at their next visit 4-6 weeks after cessation of drugs because of an expected rapid return of hypertension, based on previous observed or reported high diastolic pressure. Three others were studied 5-21 weeks after discontinuance of drugs because of high systolic blood pressure. Two were studied 9-16 weeks after stopping drugs when repeated measurements showed no upward trend of blood pressure. This protocol for the repeat measurement was chosen because patients with a rapid recurrence of hypertension would not be at risk for an unduly long time and because a long interval, when safe, would allow fuller recovery of glycohemoglobin. With this protocol no patient developed angina or "overshoot" hypertension. One patient had headaches and a return of blood pressure to pretreatment levels 3 weeks after cessation 
Results
Data from patients withdrawn from diuretic monotherapy and from combination therapy were combined in this report because the directional changes of all measurements of interest were similar for both forms of therapy. In fact, total serum cholesterol decreased significantly after withdrawal of diuretics (238 to 223 mg/dl, p < 0.01) and after withdrawal of combination therapy (231 to 210 mg/dl, p < 0.025). Triglyceride decreased significantly after discontinuation of combination therapy (144 to 101 mg/dl, p < 0.01), but not after discontinuance of diuretic therapy (112 to 98 mg/dl, 0.1 > p > 0.05). The ratio of total cholesterol to HDL cholesterol decreased significantly after discontinuance of diuretic therapy (5.1 to 4.5, p < 0.02), but not after discontinuance of combination therapy (5.1 to 4.6, p > 0.1). Glycohemoglobin was significantly lower after cessation of combination therapy (7.9 to 7.2%, p < 0.02), but not after cessation of diuretic monotherapy (7.9 to 7.1%, 0.1 > p > 0.05). Because of these parallelisms, the two treatment groups were combined (table 2) . Total serum cholesterol, triglyceride, and glycohemoglobin decreased significantly after withdrawal of antihypertensive drug therapy. LDL, VLDL and HDL cholesterol as well as lipoprotein lipase did not change significantly. The ratio of total cholesterol to HDL cholesterol declined significantly. Serum glucose concentrations were lower after withdrawal of antihypertensive drugs ( fig. 1 ). Serum insulin also declined, but not significantly, after treatment was stopped.
The correlative data showed a direct linear relationship between changes in fasting glucose and changes in glycohemoglobin after discontinuation of drug treatment (r = 0.49, p < 0.02). The change in the sum of fasting glucose plus 30-minute and 1-hour glucose, here termed total glucose, also correlated with the change in glycohemoglobin (r = 0.41, p < 0.05). The absolute values of glycohemoglobin also correlated with the absolute values of several indexes of glucose metabolism during therapy, including fasting glucose (r = 0.46, p < 0.02), 30-minute glucose (r = 0.55, p < 0.01), 1-hour glucose (r = 0.43,p < 0.05) and total glucose (r = 0.41, p < 0.05).
We found a correlation between changes in glycohemoglobin and changes in triglyceride after discontinuance of drug therapy ( therapy. This insulin pattern, together with increased glucose concentrations in our patients during antihypertensive therapy, suggest that insulin resistance is a more common cause of the carbohydrate intolerance. Further study is needed to ascertain whether abnormal insulin, altered receptors, postreceptor events, or other factors contribute to the apparent insulin resistance.
The elevations in fasting, 30-minute and 1-hour glucose values during therapy seem minor, representing increases of 9.5%, 13.9% and 14.3%, respectively, above the postdrug values. Nevertheless, this slight abnormality was accompanied by an increase in glycohemoglobin from 7.2% to 7.9% during therapy, an increment proportional to that of glucose. Thus, even mild disturbances of glucose metabolism can increase the glycosylation of hemoglobin. If glycosylation of hemoglobin and other proteins presages diabetic complications, then this metabolic alteration may not be trivial. More information is needed about the prognostic implications of raised glycohemoglobin. In accord with the findings of others and the acknowledged relationship of serum glucose to glycohemoglobin,20 22 we noted positive linear correlations between the change in fasting glucose and the change in glycohemoglobin. We also noted positive relationships between the absolute values of glucose and glycohemoglobin during therapy. Glycohemoglobin correlated with fasting glucose about as well as with any other index of carbohydrate metabolism.
In contrast to the correlations during therapy, glucose and glycohemoglobin did not correlate in the posttherapy period. The lack of relationship between glucose and glycohemoglobin in the postdrug period may be because the measurements were made only 7 weeks, on average, after discontinuation of the drugs, an interval perhaps too brief to restore glycohemoglobin to basal values. In fact, 19 studies were conducted only 3-4 weeks after cessation of drug therapy. Glycosylation of hemoglobin is considered to be a relatively slow and irreversible reaction12 and normal red cells have a life of 4 months; thus, the erythrocytes with excessive glycohemoglobin may not have been completely eliminated in some patients. A discrepancy of lag times for normalization of the defects may have obscured a relationship after termination of drug therapy. Correlations during therapy may have been of a higher order because measurements were obtained after prolonged therapy (table 1) , a circumstance favorable to stabilization of glycohemoglobin at steady-state concentrations.
The correlations between glucose and lipid concentrations do not prove a causal relationship, but the correlations seem too numerous to be accounted for by chance alone. Systolic and diastolic blood pressure, serum potassium, uric acid, and chloride are affected by diuretic-based antihypertensive therapy, but these variables did not correlate regularly with serum lipid and lipoprotein concentrations in our study. Other iinvestigators have reported correlations between serum lipid concentrations and glucose or glycohemoglobin.23 24 Taken together, the evidence points to a common mechanism of the glucose and lipid alterations during diuretic-based antihypertensive therapy. We offer the following tentative explanation to link the metabolic derangements in glucose and lipid metabolism. Insulin resistance is the critical abnormality, and it has several consequences. First, it impairs utilization of glucose, thereby decreasing the availability of glucose for energy requirements and increasing serum glucose concentrations. Second, the state of resistance weakens the inhibitory effect of insulin on lipolysis. As a result of this and perhaps because of the impaired utilization of glucose, fat stores are mobilized. Fat mobilization accelerates fatty acid transport to the liver. The fatty acids are, in part, esterified to triglycerides and secreted in VLDL. VLDL concentrations increase in blood and by 8 .8%. Thus, the probability of myocardial infarction would not be reduced by the drug therapy, owing to the metabolic derangements. In 35-year-old men, in whom total cholesterol exerts a stronger impact on the subsequent development of myocardial infarction, equivalent metabolic alterations and changes in blood pressure would raise the probability of myocardial infarction in 6 years from 0.9% to 1.2%, a relative increase of 33%. The imprecision of these risk estimates is attested by the fact that the Hypertension Detection and Follow-up Program (HDFP) demonstrated a decrease in myocardial infarction after prolonged drug treatment of hypertension.26 Nevertheless, our findings may explain, in part, why persons less than 50 years old in the HDFP experienced no reduction in mortality even though enormous numbers of them (n = 2400) were treated for an extended period (5 years).27 We do not advocate that drug therapy be withheld, because the complications of hypertension that are largely pressuredependent, that is, stroke and congestive heart failure, benefit from the lowering of pressure.28 However, alternative therapies, other than more intensive drug regimens, may be required in hypertension for additional lowering of the incidence of myocardial infarction and other complications of atherosclerosis.
